Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Amortization of Deferred Charges (2019 - 2024)

Historic Amortization of Deferred Charges for Fennec Pharmaceuticals (FENC) over the last 8 years, with Q4 2024 value amounting to -$1.1 million.

  • Fennec Pharmaceuticals' Amortization of Deferred Charges fell 201272.73% to -$1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $52000.0, marking a year-over-year decrease of 7647.06%. This contributed to the annual value of $52000.0 for FY2024, which is 7647.06% down from last year.
  • As of Q4 2024, Fennec Pharmaceuticals' Amortization of Deferred Charges stood at -$1.1 million, which was down 201272.73% from $301000.0 recorded in Q3 2024.
  • Fennec Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $405000.0 during Q2 2024, with a 5-year trough of -$1.1 million in Q4 2024.
  • Its 5-year average for Amortization of Deferred Charges is $50133.3, with a median of $53000.0 in 2023.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 198823.53% in 2020, then plummeted by 201272.73% in 2024.
  • Fennec Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $355000.0 in 2020, then tumbled by 97.75% to $8000.0 in 2021, then soared by 587.5% to $55000.0 in 2022, then changed by 0.0% to $55000.0 in 2023, then plummeted by 2012.73% to -$1.1 million in 2024.
  • Its Amortization of Deferred Charges stands at -$1.1 million for Q4 2024, versus $301000.0 for Q3 2024 and $405000.0 for Q2 2024.